SMR 2024 | Enhancing ctDNA monitoring for prime time use in high-risk melanoma
Meghan Mooradian, MD, Massachusetts General Hospital, Boston, MA, reviews how current research can improve circulating tumor DNA (ctDNA) monitoring before prime time use for patients with high-risk melanoma. Improved technology to increase the sensitivity of ctDNA assays without compromising specificity is necessary to better understand the location of metastases and its impact on ctDNA shedding and detection in patients that relapse. Expanding the number of mutations available for monitoring with whole genome sequencing and exploring different ways to alter ctDNA clearance can improve the sensitivity of ctDNA assays in the future. This interview took place at the 21st International Congress of the Society for Melanoma Research (SMR) in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
